Ameriprise Financial Inc Oncternal Therapeutics, Inc. Transaction History

Ameriprise Financial Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.83 - $17.8 $7,885 - $169,100	-9,500 Reduced 34.64%	17,921 $16,000
Q2 2022 Aug 15, 2022	SELL	$0.7 - $1.56 $6,066 - $13,518	-8,666 Reduced 24.01%	27,421 $30,000
Q1 2022 May 16, 2022	SELL	$1.37 - $2.43 $6,606 - $11,717	-4,822 Reduced 11.79%	36,087 $50,000
Q4 2021 Feb 14, 2022	SELL	$2.27 - $4.39 $47,992 - $92,813	-21,142 Reduced 34.07%	40,909 $93,000
Q3 2021 Nov 15, 2021	SELL	$3.37 - $4.76 $19,080 - $26,951	-5,662 Reduced 8.36%	62,051 $259,000
Q2 2021 Aug 16, 2021	SELL	$4.75 - $9.39 $1.75 Million - $3.45 Million	-367,511 Reduced 84.44%	67,713 $322,000
Q1 2021 May 17, 2021	BUY	$4.59 - $9.04 $2 Million - $3.93 Million	435,224 New	435,224 $3.62 Million

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.